The historical rank and industry rank for AB Science's Days Payable or its related term are showing as below:
XPAR:AB'
s Days Payable Range Over the Past 10 Years
Min: 6585.72 Med: 30287.94 Max: 80235.24
Current: 10917.72
During the past 13 years, AB Science's highest Days Payable was 80235.24. The lowest was 6585.72. And the median was 30287.94.
XPAR:AB's Days Payable is ranked better than 98.91% of 921
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs XPAR:AB: 10917.72
AB Science's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
AB Science Days Payable Related Terms
AB Science Days Payable Historical Data
* Premium members only.
The historical data trend for AB Science's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:AB vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AB Science's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AB Science Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AB Science's Days Payable distribution charts can be found below:
* The bar in red indicates where AB Science's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
AB Science's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AB Science (XPAR:AB) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AB Science and its competitors. Over the past decade, AB Science's Days Payable has ranged from 6,585.72 to 80,235.24. According to the industry distribution chart, AB Science ranks #10 out of 921 companies in the Drug Manufacturers industry, placing it in the top 1.1%.
Is AB Science's Days Payable too high?
AB Science's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 6,585.72 to a high of 80,235.24. Based on the distribution chart, AB Science ranks #10 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AB Science has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AB Science's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AB Science ranks #10 out of 921 companies for Days Payable. This places AB Science in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.69. Historically, AB Science's own Days Payable has ranged from 6,585.72 to 80,235.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AB Science and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AB Science's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AB Science stock overvalued right now?
Based on GuruFocus' analysis, AB Science (XPAR:AB) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.89 — trading 39.8% below its estimated fair value. The current Days Payable is 0.00. AB Science's overall GF Score™ is 56/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For AB Science (XPAR:AB), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AB Science (XPAR:AB) Overvalued in 2026?
Based on GuruFocus' analysis, AB Science stock appears to be undervalued.
The current stock price of €0.89 is trading 39.8% below its estimated GF Value™ of €1.47.
GuruFocus considers AB Science to be Possible Value Trap.
Key valuation signals for XPAR:AB:
Days Payable: 0.00
GF Value™: €1.47 vs. price of €0.89 (39.8% below fair value)
No single metric tells the full story. See the XPAR:AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
56GF Score
Get the complete analysis for XPAR:AB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:AB has been successfully added to your 
